	-1449			Docket Number 3996320	001920	Application Nu	mber PRECEIV
OUNE PRIMATION DISCLOSURE CITATION				Applicant	Applicant		
IN AN APPLICATION					Alessandro	SETTE, et al.	AUG 0 2 20
JIL 1 2 2002 (Use several sheets if necessary)				Filing Date November 1	0, 1998	Group Art Unit	1644
DUL 1 - ZOCE	3			Mailing Date July 5, 2	002	RE	CEIVED TER 1
TRADEMARY	// _					/	
1140						JUL	1 7 2002
			U.S. PAT	ENT DOCUMENTS		TECH CEN	JTÉR 1600/2900
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date If
Initials	No.					/	Appropriate
	1.	07/1986	4,599,230	Milich et al.	424	189.1	
	2.	07/1991	5,028,425	Good et al.	424 /	191.1	COPY OF PAPERS
	3.	08/1994	5,342,774	Boon et al.	435		ORIGINALLY FILED
	4.	04/1993	5,200,320	Sette et al.	435/	7.24	
	5.	04/1995	5,405,940	Boon et al.	580	328	
	6.	10/1995	5,462,871	Boon-Falleur et al.	435	354	1)_/
	7.	04/1996	5,503,829	Ladant et al.	424	192.1	10
	8.	09/1997	5,662,907	Kubo et al.	424	185.1	1
	9.	04/1998	5,736,142	Sette et al.	424	183	<u> </u>
	10.	05/1998	5,750,395	Fikes et al.	435	325	
	11.	11/1998	5,840,303	Chisari et al.	424	152.1	
	12.	03/2000	6,037,135	Kubo et al	435	7.24	
	13.	05/2000	6,063,900	Melief et al.	530	327	
	14.	06/2000	6,075,122	Cheeyer et al.	53,0	350	
	1	T -		PATENT DOCUMEN	FTS Class	Subclass	Translation
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Succiass	YES NO
	15.	01/1982	EP 44710 /	Europe			
	16.	06/1987	EP 0226513	Europe			
	17.	06/1989	EP 0346022	Europe		ļ	
	18.	08/1996	EP 0534615	Europe		ļ	
:		20/2006	EP 0728764	Europe			
!	19.	08/1996	EF 9/20/04				
!	19. 20.	08/1996	W/O 92/02543	WIPO	8		<u> </u>
:				WIPO WIPO		7	ly in the second

conformance and not considered. Include a copy of this form with next communication to applicant.

\SB/ 08 (2-92)

Application Number 09/189,702

MU	AN AN APPLICATION			AUG 0 2 20					
Use several sheets if necessary)			Filing Date November 10	, 1998	Group Art Unit	1644 AUG	0 2 200		
			Mailing Date July 5, 2002 TECH C		TECH CE	NTER 160			
ADFW									
	23.	03/1993	WO 93/03753	WI	PO		REC	EIVE	D
	24.	03/1993	WO 93/03764	WI	PO				
	25.	09/1993	WO 93/17095	WI	PO		JUL	7 2002	<u></u>
	26.	11/1993	WO 93/22338	WI	PO				
	27.	02/1994	WO 94/03205	WI	PO		TECH CEN	TER 1600) ₂₉₀₀
	28.	03/1994	WO94/05304	WI	PO				
	29.	05/1994	WO 94/11738	WI	PO		CORY	OF PAPER	L
	30.	04/1995	WO 95/11255	WI	PO			ALLY FILE	
	31.	08/1995	WO 95/23234	WI	PO				
	32.	02/1997	WO 97/04802	WI	PO				
	33.	08/1997	WO 97/29195	WI	PO				
			OTH	ER D	OCUMENTS	(including	author, title, De	ate, Pertinent	Pages, Etc.)
Examiner Initials	Ref. No.	Title							
	34.	Alexander et al. "Generation of Tumor-specific Cytolytic T Lymphocytes from Peripheral Blood of Cervical Cancer Patients by In Vitro Stimulation with a Synthetic Human Papillomavirus Type 16 E7 Epitope" Am. J. Obstet. Gynecol. 175:1586-1593 (1996)							
35. Alexander et al., J. Immunol. (1997) 159:4753-4761									
	36.	Altfeld et a	al., J. Virol. (2001) 7:	5:1301	-1311				
	37.	Benjamin et al., Nature (1991) 351:74-77							
	38.	Bergmann et al., J. Virol. (1994) 68:5306-5310							
	39.	Bertoni et al., J. Clin. Invest. (1997) 100:503-513							
	40.	Bjorkman et al. "Structure of the Human Class I Histocompatibility Antigen HLA-A2" Nature 329:506 (1987)							
	41.	Boel et al., Immunity (1995) 2:167							
	42.	Boon. Turnor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy" Int. J. Cancer 54:177-180 (1993)							
	43.	Bosisio et al., Gazz. Chim. Ital. (1967) 97(12):1848-1857							
	44.		Short Linear Sequence quired from Virion F					us Envelo	pe
	45.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science 242:1045-1047 (1988)							
EXAMI	NER:	X)/(K	AA		DATE CONSI	DERED:	de do con	3 4	
			nsidered, whether or not to Include a copy of this for				ne through the	citation if n	ot in
PTO/SB/ 08		-			Patent and Trader		DEPARTM	ENT OF CO	MMERCE

Docket, Number 399632001920

Applicant

FORMATION DISCLOSURE CITATION

Form PTO-1449			Docket Number 399632001920	Application Number 09/189,702	8		
NEORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Applicant Alessandro	SETTE, et al.	ECH CENTER 1600/2900		
			Filing Date November 10, 1998	Group Art Unit 1644	=		
Use several sneets ty necessary)			Mailing Date July 5, 2002	5 7	Ħ		
TIME	0/-			<u> </u>	ᄧ		
DE TOP	16 .	Carreno et al. "HLA-B37 and HLA-A2 Proc. Natl. Acad. Sci. USA 87:3420-34		overlapping Sets of Peptides	<u>"</u> 🖺		
4	47.	Castellanos et al., Gynecologic Oncolo	ogy (2001) 82:77-83				
4	48.	Castellanos et al., Oncology/Hematolo	gy (2001) 39:133-138				
4	19.	Celis et al. "Identification of Potential Common HLA-A Alleles" Molec. Imm		ated Antigen MAGE-1 for Fi	y 2002 7007		
:	50.	Celis et al. "Epitope Selection and Dev Biology 6:329-336 (1995)	velopment of Peptide Based Vac	cines to Treat Cancer" Cance	1 9		
:	51.	Chang et al., J. Immunol. (1999) 162:1	156-1164	ii «	話		
	52.	Chen and Parham, Nature (1989) 337:	743-745	Ü Ü	湛		
	53.	Cotran et al. (ed.) Robbins Pathologic 296-299 (1989)	Basis of Disease, 4th ed., W.B. S	aunders Co., Philedelphia pp	, 0		
	54.	Culmann et al., (1991) 146(5):1560-15	665		#		
	55.	De Bruijn et al. "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses" Eur. J. Immunol. 21:2963-2970 (1991)					
	56.	Del Val et al., Cell (1991) 66:1145-1153					
	57.	DiBrino et al. "Endogenous Peptides Bound to HLA-A3 Possess a Specific Combination of Anchor Residues That Permit Identification of Potential Antigenic Peptides" Proc. Nat'l. Acad. Sci. USA 90:1508-1512 (1993)					
	58.	Dibrino et al., J. Immunol. (1993) 151:	:5930-5935				
	59.	Diepolder et al., J. Virol. (1997) 71(8):	3):6011-6019				
	60.	Ding et al. "Cloning and Analysis of M 202(1):549-555 (1994)	AAGE-1-Related Genes" Bioche	m. Biophys. Res. Commun.			
1	61.	Ding et al., Immunity (1998) 8:403-41	1				
	62.	Doolan et al., Immunity (1997) 7:97-1	12		\neg		
	63.	Doolan et al., J. Immunol. (2000) 165:	1123-1137				
	64.	Edgington. "How Sweet It Is: Selecting	in-Mediating Drugs" Biotechnology 10:383-389 (1992)				
- 1	65.	Eisenlohr et al., J. Exp. Med. (1992) 1	75:481-487				
(66.	Engelhard et al. "Structure of Peptides Associated with MHC Class I Molecules" Curr. Opin. Immunol. 6:13-23 (1994)					
- 1	67.	Falk et al., J. Exp. Med. (1991) 174:42	5-434				
	68. Falk et al. "Allele-specific Motifs Revealed by Sequencing of Self-peptide Eluted from MHC Molecules" Nature 351:290-296 (1991)						
EXAMINI	ER:	Mess	DATE CONSIDERED:	5/3/12003			
		al if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

n PTO-144	9	Docket Number 399632001920	Application Number (1971)9,	neet 4 of 702		
	TION DISCLOSURE CITATION N AN APPLICATION	Applicant Alessanda	ro SETTE, et al.	7 200		
6	(Use several sheets if necessary)	Filing Date November 10, 1998	Group Art Unit 1644	-		
		Mailing Date July 5, 2002	Ш	3		
ADEM BRECE			Œ			
69.	Feltkamp et al. "Vaccination with C Against a Tumor Induced by Huma 23:2242-2249 (1993)	Cytotoxic T Lymphocyte Epitope n Papillomavirus Type 16-transfo	containing Peptide Prote ormed Cells" Eur. J. Imm	ects nunol.		
70.	Foon. "Biological Response Modifi	ers: the New Immunotherapy" Ca	ancer Res. 49:1621-1639	(1989)		
71.	Fynan et al. "DNA Vaccines: Protections" Proc. Nat'l. Acad. Sci		Mucosal, and Gene-gun) 2002		
72.	Gambacorti-Passerini et al., Clin. C	ancer Res. (1997) 3:675-683	≥	2		
73.	Gaugler et al. "Human Gene MAGI Autologous Cytolytic T Lymphocyt			0 9		
74.	Gavioli et al., Proc. Natl. Acad. Sci	. USA (1992) 89:5862-5866	Ц	AU A		
75.	Gonzalez et al., Parasite Immunolog	gy (2000) 22:501-514				
76.	Guo et al., Nature (1992) 360:364-3	366				
77.		Hayashi et al. "Molecular Cloning and Characterization of the Gene Encoding Mouse Melanoma Antigen by cDNA Library Transfection" J. Immunol. 149:1223-1229 (1992)				
78.		Henderson et al. "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation" Science 255:1264-1266 (1992)				
75.	Hill et al., Nature (1992) 360:434-439					
80.	Huczko et al., J. Immunol. (1993) 1	51:2572-2587				
81.	Hunt et al. "Characterization of Per Spectrometry" Science 255:1261-12		Molecule HLA-A2.1 by	Mass		
82.	Hurtenbach et al. "Prevention of Au with a Class II Major Histocompati (1993)	atoimmune Diabetes in Non-Ober bility Complex-blocking Peptide	se Diabetic Mice by Trea J. Exp. Med. 177:1494	tment -1504		
83.	Ishioka et al., J. Immunol. (1999) 1	62:3915-3925				
84.	Jameson and Bevan, Eur. J. Immun	ol. (1992) 22:2663-2667				
85.	Jardetzky et al. "Identification of Se (1991)	elf Peptides Bound to Purified HI	A-B27" Nature 353:326	5-329		
86.	Jiang et al. "Role of CD8* T Cells i 256:1213-1215 (1992)	in Murine Experimental Allergic	Encephalomyelitis" Scie	nce		
87.	Kannagi et al. "Target Epitepe in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells" J. of Virol. 66(5):2928-2933 (1992)					
88.	Karin et al J. Exp. Med. 180:2227-2	2237 (1994)				
89.	Kast et al., J. Immunol. (1994) 152:	3904-3912				
EXAMINER:	NA	DATE CONSIDERED:	da Inos	2		

Form PTO-1449			Dockét Number 399632001920	Application Number 09/189,702			
O THE PRIMATION DISCLOSURE CITATION			Applicant	 			
IN AN APPLICATION			Alessandro	SETTE, et al.			
Use several sheets if necessary)			Filing Date November 10, 1998	Group Art Unit 1644			
			Mailing Date July <u>5</u> , 2002				
PRADENT	*/			8 8			
THAUT	90.	Kast et al., Eur. J. Immunol. (1993) 23	:1189-1192	2002 2002			
	91.	Kawakami et al., J. Immunol. (1995) 1	54:3961-3968	<u> </u>			
	92.		pe Approach for Immunotherapy for Cancer: Identification of Tumor-Associated Antigens Expressed on Solid Epithelial 59:1-14				
	93.	Knuth et al. "Cellular and Humoral Im Vaccines" Curr. Opinion Immunol. 3:6		r: Implication for Cancer			
	94.	Koh et al. "Less Mortality but More R Mice" Science 256:1210-1213 (1992)	elapses in Experimental Allergic	Encephalomyelitis in CDB-			
	95.	Kozlowski et al., J. Exp. Med. (1992)	175:1417-1422				
	96.	Krieger et al. "Single Amino Acid Cha MHC Binding and T Cell Recognition					
	97.	Lamonica et al., Hepatology (1999) 30	30:1088-1098				
	98.	Lehniger. "Principles of Biochemistry"	ry" Worth Publishers, Inc. NY; pp. 100-101 (1982)				
	99.	Lipford et al., J. Immunol. (1993) 150:	:1212-1222				
	100.	Lustgarten et al., "Identification of He Expressing HLA-A2.1 and Human CD					
	101.	Maier et al., (1994) 40:306-308					
	102.	Maryanski et al. "Competitor Analogs Binding Motif and Polyproline or Poly					
	103.	Melief et al. "T-Cell Immunotherapy of	of Cancer" Res. Immunol. 142:4	25-429 (1991)			
	104.	Melief et al., Cancer Surveys (1992) 1	13:81-99				
	105.	Miller et al. "Suppressor T Cells Gene Both In Vitro and In Vivo Immune Re Antigen-specific Triggering" Proc. Na	sponses by the Release of Trans	forming Growth Factor β After			
	106.	Morrison et al. "Identification of the Nonamer Peptide from Influenza A Matrix Protein and the Role of Posckets of HLA-A2 in Its Recognition by Cytotoxic T Lymphocytes" Eur. J. Immunol. 22:903-907 (1992)					
	107.	Niedermann et al., Immunol. Rev. (19	999) 172:29-48				
	108.	Niedermann et al., Proc. Natl. Acad. S	ci. USA (1996) 93:8572-8577				
	109.	Oaks et al. "Molecular Cytogenetic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qtr: Implications for MAGE Immunotherapy" Cancer Res. 54:1627-1629 (1994)					
	110. Ochoa-Garay et al. Molecular Immunology 34:273-281 (1997)						
EXAMI	NER:	Valor	DATE CONSIDERED:	X/2/2003			
EXAMIN	ER: Initi	al if citation considered, whether or not the citation	on conforms with MPEP 609. Draw a	line through the citation if not in			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449			Docket Number 399632001920	Application Number 09/189,702			
O TIPE RMATION DISCLOSURE CITATION O IN AN APPLICATION			Applicant Alessandro SETTE, et al.				
-	<u>د</u> ا	se several sheets if necessary)	Filing Date November 10, 1998	Group Art Unit 1644			
UL 1 2 2002 (Use several sheets if necessary)			Mailing Date July 5, 2002	TR 17			
2.	gray -			8 20			
THAUFA	111.	Pamer et al. "Precise Prediction of a D Monocytogenes" Nature 353:852-855					
	112.	Parker et al. "Peptide Binding to HLA Chem. 267(8):5451-5459 (1992)	-A2 and HLA-B27 Isolated from	n Escherichia coli" J. Biol.			
	113.	Parker et al. "Sequence Motifs Importa HLA-A2" J. Immunol. 149:3580-3587		uman MHC Class I Molecule,			
	114.	Parker et al. "Scheme for Ranking Pot Binding of Individual Peptide Side-Ch					
	115.	Paul (ed.), Fundamental Immunology,					
	116.	Paul (ed.), Fundamental Immunology,	3rd ed., Raven Press, NY, pp. 97	76-978 (1993)			
	117.		cleotide Sequence of a Hepatitis B Virus, Subtype adw2, and ppen Reading Frames" Nucleic Acids Res. 21:2258 (1993)				
	118.	Prezzi et al., Eur. J. Immunol. (2001)	31:894-906				
	119.	Rammensee et al. "Peptides Naturally 11:213-244 (1993)	Presented by MHC Class I Mol	ecules" Annu. Rev. Immunol.			
	120.	Rammensee et al. "MHC Ligands and (1995)	Peptide Motifs: First Listing" In	nmunogenetics 41(4):178-228			
	121.	Rammensee et al. "SYFPEITHI: Data 50(3-4):213-219 (1999)	base for MHC Ligands and Pept	ide Motifs" Immunogenetics			
	122.	Rehermann et al., J. Clin. Invest. (199					
	123.	Ressing et al. "Human CTL Epitopes Identified Through In Vivo and In Vit J. Immunol. 154:5934 (1995)					
	124.	Rickinson. "Immune Intervention Aga 6(Supp. 1): 69-71 (1995)	ninst Virus-associated Human Ca	ancers" Annals of Oncology			
	125.	Rivoltini et al., J. Immunol. (1995) 15	4:2257-2265				
	126.	Romero et al. "H-2Kd-restricted Antig 174:603-612 (1991)	genic Peptides Share a Simple B	inding Motif' J. Exp. Med.			
	127.	Rothbard, Current Opinion in Immuno	ology (1989) 2:99-105				
	129.	Rotzschke et al. "Characterization of I Including H-4 and H-Y" 249:283-287		compatibility Peptides			
	129.	 Rotzschke et al. "Isolation and Analysis of Naturally Processed Viral Peptides As Recognized by Cytotoxic T Cells" Nature 348:252-254 (1990) 					
	130.	Rotzschke et al. "Naturally Occurring Processing Pathway" Immunology To	Peptide Antigens Derived from day 12(12):447-455(1991)	the MHC Class-I-restricted			
EXAMI	NER:	Man	DATE CONSIDERED:	5/34/200			
EXAMI	NER: Initi	ial if citation considered interpretary hourse distinct	ion conforms with MPEP 609. Draw a	line through the citation if not in			

'AUG 3 2 2002

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449			Docket Number 399632001920	Application Number 09/189,702	
INFORMATION DISCLOSURE CITATION			Applicant		
ON AN APPLICATION			Alessandro SETTE, et al.		
1 2 2002 (Use several sheets if necessary)			Filing Date November 10, 1998	Group Art Unit 1644	
			Mailing Date July €, 2002		
Car.	Mode				
PRADE	131.	Rotzschke et al. "Peptide Motifs of Cl Differences" Eur J. Immunol. 22:2453	osely Related HLA Class I Mole -2456 (1992)	ecules Encompass Substantial	
	132.	Rudinger. "Characteristics of the Amin Peptide Hormones, Parsons (ed.), Univ	no Acids As Components of a P versity Park Press, pp. 1-7 (1976	eptide Hormone Sequence" in	
	133.	Ruppert et al. "Prominent Role of Second Molecules" Cell 74(5):929-937 (1993)			
	134.	Sarobe et al. "Induction of Antibodies Between the Hapten and a Class II Pre (1991)	es Against a Peptide Hapten Does Not Require Covalent Linkage resentable T Helper Peptide" Eur. J. Immunol. 21:1555-1558		
	135.	Schaeffer et al. Proc. Natl. Acad. Sci.	USA 86:4649 (1989)		
	136.	Scognamiglio et al., J. Immunol. (199			
	137.	Sette et al. "Prediction of Major Histo Analysis" Proc. Nat'l. Acad. Sci. USA	ocompatibility Complex Binding Regions by Sequence Pattern		
	138.	Sette et al. "Random Association betw Different DR Class II Molecules" J. In	veen the Peptide Repertoire of A mmunol. 147:3893-3900 (1991)	2.1 Class I and Several	
	139.	Sette et al., J. Immunol. (1994) 153:55	586-5592		
	140.	Sette and Sidney, Curr. Opin. Immuno	ol. (1998) 10:478-482		
	141.	Sette et al., in Persistent Viral Infection	ons, Ahmed and Chen (Eds.), Jol	nn Wiley & Sons (1999)	
	142.	Sette et al., Immunodominance and B	readth of Cellular Responses (20	001) In Press	
	143.	Shanker et al. "Three Regions of HIV (Abstracr) Immunology Letters 52(1):		amunodominant CTL Epitopes"	
	144.	Shastri et al., J. Immunol. (1995) 155:	4339-4346		
	145.	Sherman et al., J. Exp. Med. (1992) 1	75:1221-1226		
	146.	Shimojo et al. "Specificity of Peptide 143(9):2939-2947 (1989)	Binding by the HLA-A2.1 Mole	ecule" J. of Immunol.	
	147.	Slingluff et al. "Recognition of Huma Lymphocytes Is Mediated by At Leas (1993)	n Melanoma Cells by HLA-A2. t Six Shared Peptide Epitopes".	1-restricted Cytotoxic T J. Immunol. 150:2955-2960	
	148.	Snoke et al., J. Immunol. (1993) 151:	6815-6821		
	149.	Storkus et al. "Identification of Huma Infiltrating T Lymphocytes" J. Immur	n Melanoma Peptides Recogniz nol. 151:3719-3727 (1993)	ed by Class I Restricted Tumor	
	150.	Tangri et al., Journal of Experimental	Medicine (2001) In Press		
	151.	Threlkeld et al., J. Immunol. (1997) 1	59:1648-1657		
	152.	Traversari et al. "A Nonapeptide Enc		Is Recognized on HLA-A1 by	
	INER:	VA	DATE CONSIDEREDA	8/31/2003	
EXAM conform	INER: Ini	tial if citation considered, whether or not the citation considered. Included a copy of this form with			
PTO/SB/ 0	8 (2-92)		Patent and Trademark Office; I	U.S. DEPARTMENT OF COMMERCE	

AUG 0 2 2002

Form PTO-1449			Docket Number 399632001920	Application Number 09/189,702			
ATION DISCLOSURE CITATION AN APPLICATION			Applicant Alessandro SETTE, et al.				
	(c)	e several sheets if necessary)	Filing Date November 10, 1998	Group Art Unit 1644			
NA 1 7 2002			Mailing Date July 5, 2002				
132	(t)						
A MAUF		Cytolytic T Lymphocytes Directed Ag (1992)	ainst Tumor Antigen MZ2-E" J.	Exp. Med. 176:1453-1457			
	153.	Tsai et al., J. Immunol. (1997) 1796-13					
	154.	Urban et al. "Autoimmune T Cells: Im Peptide-Based Therapy" Cell 59:257-2	271 (1989)				
	155.	Van der Bruggen et al. "A Gene Encoo Human Melanoma" Science 254:1643	ding an Antigen Recognized by -1647 (1991)	Cytolytic T Lymphocytes on a			
	156.	Van Der Most et al., J. Immunol. (199	6) 157:5543-5554				
	157.	Van Der Most et al., Virology (1997)	71:5110-5114				
	158.	Van Der Most et al., Virology (1998)					
	159.	Viret et al. "Recognition of Shared Me Clones Derived from Human Tumor-i	nfiltrating Lymphocytes" Eur. J.	Immunol. (1993)			
	160.	Vitiello et al. "Development of a Lipo Infection" J. Clin. Invest. 95:341-349	peptide Based Therapeutic Vacc (1995)	ine to Treat Chronic HBV			
	161.	Vitiello et al., J. Immunol. (1996) 157	:5555-5562				
	162.	Wei et al. "HLA-A2 Molecules in an A Sequencederived Peptides" Nature 35	Antigen-Processing Mutant Cell	Contain Signal			
	163.	Wentworth et al., Eur. J. Immunol. (19	996) 26:97-101				
	164.	Weynants et al. "Expression of MAGI 56:826-829 (1994)	E Genes by Non-Small-Cell Lun	g Carcinomas" Int. J. Cancer			
	165.	Wilson et al., J. Virol. (2001) 75:4195	-4207				
	166.	Wizel et al., J. Clin. Invest. (1998) 10:	2:1062-1071				
	167.	Wraith et al. "Antigen Recognition in Mediated Immunotherapy" Cell 59:24	Autoimmune Encephalomyeliti 17-255 (1989)	s and the Potential for Peptide-			
	168.	Wysocka et al. "Class I H-2d-Restrict Glycoprotein of Influenza Virus Subty	ed Cytotoxic T Lymphocytes Re ype N1" Journal of Virology 64(ecognize the Neuraminidase 3):1028-1032 (1990)			
	169.	Yewdell and Bennick, Annu. Rev. Im-					
	170.	Yoon et al., Virus Research (1998) 54	:23-29				
	171.	York and Rock, Annu. Rev. Immunol					
	172.	Zakut et al, "Differential Expression of MAGE-1, -2, and -3 Messenger RNA in Transformed and Normal Human Cell Lines" Cancer Res. 53:5-8 (1993)					
	173. Zhang et al., Proc. Natl. Acad. Sci. USA (1993) 90(6):2217-2221						
EXAMI		XVV	DATE CONSIDERED:	J(31/2003			
conforma	ince and i	ial if citation considered, whether or not the citat not considered. In the Copy of the com with	next communication to applicant.	I.S. DEPARTMENT OF COMMERCE			
provenzan							

COPY OF PAPERS ORIGINALLY FILED

AUG 0 2 2002